End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.75 CNY | +0.04% | +0.22% | -9.11% |
Apr. 18 | China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy | MT |
Apr. 17 | Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator | MT |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.